Full-Time

Events Specialist

Posted on 11/1/2025

Wellington Management

Wellington Management

1,001-5,000 employees

Global asset management for institutional clients

Compensation Overview

$80k - $180k/yr

+ Corporate Bonus + Incentives

Company Historically Provides H1B Sponsorship

Boston, MA, USA + 1 more

More locations: New York, NY, USA

Hybrid

Hybrid work arrangement: in-office 4 days/week, with 1 day remote; travel as required.

Category
Growth & Marketing (1)
Required Skills
Salesforce
Marketing
Requirements
  • A solid understanding and strong interest of the investment industry, and intermediary marketing
  • Success in hosting proprietary events and participating in industry conferences targeted to the US Wealth audience
  • Ability and willingness to travel as required
  • Prior experience with in-person events, virtual events, and event management technology platforms
  • Strong written and oral communication skills
  • Solid business judgement
  • Excellent time and project management/organizational skills, including the ability to multitask, be consistently responsive, and manage changing priorities while meeting often strict deadlines
  • Proven ability to interact effectively and professionally with senior executives, internal business partners, external clients, creative teams, and external vendors
  • Demonstrated initiative, resourcefulness, and creativity; continuously seeking out ways to improve and elevate effective marketing strategies
  • Ability to manage multiple projects independently
  • Experience working as part of a global team where team members are based in multiple global offices
  • Tremendous grace under pressure
Responsibilities
  • Manage a variety of in-person and virtual events, as part of an integrated marketing strategy to build awareness and engagement in the US Wealth channels
  • Plan, design, and produce events while managing all project delivery elements within time limits
  • Create schedules for each event that documents the run of show and all program requirements
  • Lead both external and internal communications for events
  • Initiate and facilitate conversations with third party industry event providers to secure appropriate engagement opportunities and maximize impact of participation (e.g., optimal speaking slot, 1:1’s, booth coordination)
  • Coordinate and oversee all presentation prep for events, including prep meetings and event briefings
  • Facilitate post-event analysis meetings with internal stakeholders and suppliers ensuring a clear focus on ROI
  • Maintain oversight of events budget
  • Source, negotiate, and manage relationships and contracts with external suppliers, venues, and vendors to achieve the highest standards of excellence and cost efficiencies
  • Bring a continuous improvement mindset by initiating, designing, and implementing new processes related to our events function
  • Propose new ideas and creative solutions to streamline internal processes and improve the overall client experience
Wellington Management

Wellington Management

View

Wellington Management is a global investment management firm that offers equity, fixed income, multi-asset, and alternative investments to both institutional clients (such as pension funds, endowments, foundations, and insurers) and individual investors. It manages assets on behalf of clients, earning fees based on assets under management (AUM) and on investment performance. The firm relies on deep research capabilities and market insights to tailor investment strategies that meet client needs, and it integrates environmental, social, and governance (ESG) factors into its process. What sets Wellington Management apart is its broad suite of investment options combined with a commitment to ESG integration and a client-tailored approach, supported by a culture that emphasizes diversity and inclusion. The company’s goal is to help clients achieve their investment objectives by delivering disciplined, research-driven strategies and sustainable investing over the long term.

Company Size

1,001-5,000

Company Stage

N/A

Total Funding

$60B

Headquarters

Boston, Massachusetts

Founded

1933

Simplify Jobs

Simplify's Take

What believers are saying

  • $1.19T AUM as of December 2024 supports scale across 50 countries.
  • Led Encord's $60M Series C to scale AI data platform in 2026.
  • Private credit market exceeds $30T, fueling 2023-launched capabilities.

What critics are saying

  • BlackRock's $11.5T AUM erodes active fees via ETF scale.
  • Renk's €300M blocked revenue writedowns 5.09% stake value.
  • Quince lawsuit triggers $50-100M liability on Series E investment.

What makes Wellington Management unique

  • Launched Absolute Return Global Equity Fund for market-neutral alpha in volatility.
  • Expanded private real estate credit platform in 2025 with Ravi S. Anand leading.
  • Manages $40B in alternatives across 40 funds for institutional clients.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Comprehensive health coverage

Work-life balance

Financial future

Development

Company News

Radio Intereconomía
Apr 14th, 2026
Wellington launches global market neutral fund to capture alpha in volatile environment

Wellington Management has launched the Wellington Absolute Return Global Equity Fund, a UCITS vehicle employing a global market neutral strategy aimed at generating returns above cash with limited exposure to traditional markets. The fund expands Wellington's liquid alternatives offering. The launch comes amid increased market volatility and reduced stability, positioning the fund to capture alpha in challenging conditions through its market-neutral approach to global equities.

AD HOC NEWS Portal Aktiengesellschaft
Apr 12th, 2026
Wellington buys 5% stake in Renk as $339M in delayed defence contracts weigh on cash flow

Wellington Management has acquired a 5.09% stake in German defence supplier Renk Group, signalling confidence despite the company facing significant operational challenges. The US asset manager built its position through direct share purchases and equity swaps. Renk is currently contending with approximately €300 million in blocked revenue due to delayed deliveries and missing export licenses. Around €200 million in planned sales has been pushed to 2026, whilst €80-100 million in orders for Israeli tank gearbox systems await German export approval. The cash flow pressure is evident, with free cash flow reaching only €67 million last fiscal year, well below the company's 80% conversion target. Shares fell 4.34% to €52.05, extending year-to-date losses to nearly 6%. Despite near-term challenges, Renk maintains a record order backlog of €6.68 billion.

Voyager Therapeutics
Apr 10th, 2026
Voyager Therapeutics Raises $60 Million in Oversubscribed Series B Financing | Voyager Therapeutics Inc.

Gene Therapy Leader to Advance Broad Product Pipeline & AAV Product Engine   Cambridge, Mass., April 13, 2015 – Voyager Therapeutics , a gene therapy company developing life-changing treatments for fatal and debilitating diseases of the central nervous system (CNS), today announced the successful

Business Wire
Apr 2nd, 2026
Cyclerion Therapeutics and Korsana Biosciences Announce Merger Agreement

Cyclerion Therapeutics, Inc. (“Cyclerion”) (Nasdaq: CYCN) and Korsana Biosciences, Inc. (“Korsana”), a privately-held biotechnology company discovering and d...

医谷网
Mar 23rd, 2026
London gene therapy firm NightstaRx raises $45M to advance blindness treatment trials

NightstaRx, a London-based ophthalmology company developing gene therapies for inherited retinal diseases, has raised $45 million in Series C funding. Wellington Management Company and Redmile Group led the round, with participation from existing investors Syncona and New Enterprise Associates. Founded in 2013, Nightstar has four drug candidates targeting conditions including choroideremia, X-linked retinitis pigmentosa and macular degeneration. Its lead candidate, NSR AAV-REP1, uses an adeno-associated virus vector to deliver the REP-1 gene to retinal cells, potentially offering a one-time treatment for choroideremia, which causes progressive blindness. The therapy is currently in phase 1/2 trials, with positive results from 14 patients published in The Lancet. The funding will advance NSR AAV-REP1 into phase 3 trials and progress two other candidates into phase 1/2 studies.

INACTIVE